Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

101.20 -0.42 (-0.41%)

Streaming Delayed Price Updated: 3:49 PM EST, Mar 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,217,813
Open	98.98
Bid (Size)	101.15 (200)
Ask (Size)	101.24 (200)
Prev. Close	101.62
Today's Range	97.61 - 102.36
52wk Range	29.17 - 124.49
Shares Outstanding	106,313,250
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗

February 27, 2026

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.

Via The Motley Fool

Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗

February 27, 2026

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

Via The Motley Fool

Performance

YTD	+28.1%	+28.1%
1 Month	+4.2%	+4.2%
3 Month	+33.5%	+33.5%
6 Month	+156.0%	+156.0%
1 Year	+164.0%	+164.0%

More News

Revolution Medicines (RVMD) Earnings Transcript ↗

February 25, 2026

Via The Motley Fool

Revolution Medicines Inc (NASDAQ:RVMD) Reports Q4 2025 Earnings Miss, Reaffirms Key Phase 3 Timeline ↗

February 25, 2026

Via Chartmill

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗

February 25, 2026

Via The Motley Fool

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

Via The Motley Fool

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Via The Motley Fool

Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗

February 18, 2026

Via The Motley Fool

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Via The Motley Fool

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

Via The Motley Fool

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Via The Motley Fool

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

Via The Motley Fool

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Via The Motley Fool

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Via The Motley Fool

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

Via The Motley Fool

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

Via MarketMinute

Why Revolution Medicines Stock Plummeted by Almost 17% Today ↗

January 26, 2026

Via The Motley Fool

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

Via Finterra

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

Via Finterra

Stay updated with the stocks that are on the move in today's pre-market session. ↗

January 26, 2026

Via Chartmill

Revolution Medicines Stock Sinks After Merck Deal Talks Collapse ↗

January 26, 2026

Via Benzinga

Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗

January 26, 2026

Via Stocktwits

Revolution Medicines Stock Stares At Big Dip After Merck Reportedly Shelves Buyout — But Analyst Flags Opportunity ↗

January 26, 2026

Via Stocktwits

This Fund Put $3.4 Million Into Navan Despite a 60% Post-IPO Drop ↗

January 24, 2026

Via The Motley Fool

The Great Mid-Cap Rotation: Fed Rate Cuts Spark a New Bull Run for the 'Forgotten' Middle Market

January 23, 2026

Via MarketMinute

Frequently Asked Questions

Is Revolution Medicines, Inc. - Common Stock publicly traded?

Yes, Revolution Medicines, Inc. - Common Stock is publicly traded.

What exchange does Revolution Medicines, Inc. - Common Stock trade on?

Revolution Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Revolution Medicines, Inc. - Common Stock?

The ticker symbol for Revolution Medicines, Inc. - Common Stock is RVMD on the Nasdaq Stock Market

What is the current price of Revolution Medicines, Inc. - Common Stock?

The current price of Revolution Medicines, Inc. - Common Stock is 101.20

When was Revolution Medicines, Inc. - Common Stock last traded?

The last trade of Revolution Medicines, Inc. - Common Stock was at 03/03/26 03:49 PM ET

What is the market capitalization of Revolution Medicines, Inc. - Common Stock?

The market capitalization of Revolution Medicines, Inc. - Common Stock is 10.76B

How many shares of Revolution Medicines, Inc. - Common Stock are outstanding?

Revolution Medicines, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.